|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 515.75 INR | -4.24% |
|
-16.93% | -32.17% |
| 12/02 | Orchid Pharma Limited, Q3 2026 Earnings Call, Feb 12, 2026 | |
| 12/02 | Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2025 | CI |
| Capitalization | 2.73TCr 30Cr 26Cr 23Cr 22Cr 41Cr 43Cr 275.6Cr 110.13Cr 1.31TCr 111.64Cr 109.26Cr 4.69TCr | P/E ratio 2026 * |
-269x | P/E ratio 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise value | 2.54TCr 28Cr 24Cr 22Cr 21Cr 38Cr 40Cr 256.39Cr 102.45Cr 1.22TCr 103.86Cr 101.64Cr 4.37TCr | EV / Sales 2026 * |
3.16x | EV / Sales 2027 * | 1.63x |
| Free-Float |
30.16% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Orchid Pharma Limited
| 1 day | -4.42% | ||
| 1 week | -16.93% | ||
| Current month | -16.93% | ||
| 1 month | -24.36% | ||
| 3 months | -39.04% | ||
| 6 months | -27.17% | ||
| Current year | -32.17% |
| 1 week | 504.6 |  | 617.4 |
| 1 month | 504.6 | | 714.95 |
| Current year | 504.6 | | 805 |
| 1 year | 504.6 | | 979.95 |
| 3 years | 362.5 | | 1,997.4 |
| 5 years | 265 | | 2,654.25 |
| 10 years | 17.5 | | 2,654.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Manish Dhanuka
CEO | Chief Executive Officer | 58 | 31/03/2020 |
| Director of Finance/CFO | - | 29/06/2020 | |
Kapil Dayya
CMP | Compliance Officer | - | 16/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 31/03/2020 | |
Manish Dhanuka
BRD | Director/Board Member | 58 | 31/03/2020 |
Mridul Dhanuka
BRD | Director/Board Member | 44 | 31/03/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.44% | -16.93% | -44.20% | +34.94% | 30Cr | |
| -2.02% | -3.79% | +5.76% | +208.78% | 88TCr | |
| -2.31% | -1.58% | +45.12% | +55.58% | 58TCr | |
| -1.63% | +3.41% | +9.84% | +48.89% | 41TCr | |
| -2.70% | -6.98% | +12.78% | +26.12% | 36TCr | |
| +0.09% | -4.81% | +23.00% | +37.72% | 30TCr | |
| -0.87% | -5.23% | +24.34% | +56.12% | 30TCr | |
| -3.50% | -2.71% | +24.55% | +8.60% | 29TCr | |
| -3.08% | -3.09% | +16.12% | +56.55% | 20TCr | |
| -2.08% | +0.95% | +25.73% | +79.03% | 18TCr | |
| Average | -2.04% | -2.75% | +14.30% | +61.23% | 35TCr | |
| Weighted average by Cap. | -1.72% | -1.65% | +19.72% | +86.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 803.6Cr 8.75Cr 7.57Cr 6.85Cr 6.58Cr 12Cr 13Cr 81Cr 32Cr 385.02Cr 33Cr 32Cr 1.38TCr | 1.46TCr 16Cr 14Cr 12Cr 12Cr 22Cr 23Cr 147.61Cr 59Cr 700.98Cr 60Cr 59Cr 2.51TCr |
| Net income | -10Cr -11.11L -10L -9L -8L -15.23L -15.9L -1.03Cr -41.12L -4.89Cr -41.69L -40.8L -18Cr | 150.87Cr 1.64Cr 1.42Cr 1.29Cr 1.24Cr 2.25Cr 2.35Cr 15Cr 6.08Cr 72Cr 6.17Cr 6.03Cr 259.19Cr |
| Net Debt | -190.4Cr -2.07Cr -1.79Cr -1.62Cr -1.56Cr -2.84Cr -2.97Cr -19Cr -7.68Cr -91Cr -7.78Cr -7.62Cr -327.11Cr | -344.1Cr -3.75Cr -3.24Cr -2.93Cr -2.82Cr -5.14Cr -5.36Cr -35Cr -14Cr -164.86Cr -14Cr -14Cr -591.16Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | 515.75 ₹ | -4.24% | 1,57,399 |
| 05/26/05 | 538.60 ₹ | -4.71% | 1,94,455 |
| 04/26/04 | 565.25 ₹ | -5.81% | 2,07,638 |
| 02/26/02 | 600.10 ₹ | -3.17% | 94,288 |
| 27/26/27 | 619.75 ₹ | -1.24% | 2,44,478 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ORCHPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition